Should I buy West Pharmaceutical Services (WST) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $400 (+7.6 %), call made on September 23, 2026, maturing on September 23, 2027 (21 d ago).
Firm-by-firm track record on West Pharmaceutical Services
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Keybanc | 55 % | +6.4 % | 11 | $390 +5% |
| B of A Securities | 29 % | -22.8 % | 7 | $355 -5% |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
- Median price target $414, i.e. +11% from the current price ($372).
- The most reliable firm on WST, Evercore ISI Group (100% hit rate, 2 scored calls), targets $425 (call made on July 27, 2026, maturing on July 27, 2027) (+14%) in its most recent call, and $390 (call made on October 23, 2025, maturing on October 23, 2026) (+5%) in the one coming due soonest.
- 5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- High valuation (P/E ~48): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Negligible dividend (0.2% yield): your return depends mostly on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on WST
Median target $414 (+11%) · 9 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in West Pharmaceutical Services now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $414 (+11%), and Evercore ISI Group (most reliable on WST, 100%) targets $425. Weigh that against valuation (P/E ~48). This is not personalized advice.
Is it too late to invest in West Pharmaceutical Services?
Not according to analysts: the median target ($414) is still +11% above the current price ($372) (most reliable on WST: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is West Pharmaceutical Services still worth investing in?
It depends on the gap between the price ($372) and its estimated value: analysts target $414 on median (+11%), with 100% buys (most reliable on WST: Evercore ISI Group, 100%). Cross-check with their real reliability on WST and the cautions above. Information, not advice.
What's the main risk in buying WST?
High valuation (P/E ~48): strong growth is already "priced in", leaving little room for error.
→ Go deeper: the full West Pharmaceutical Services profile (consensus, analyst reliability, price target, performance).